SCHEMBL720303

SCHEMBL720303

c1ccc(-c2ccc3cc4c(cc3n2)CCNCC4)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.41
HTR2B P41595 3/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
DRD2 P14416 2/20 0.39
CYP3A4 P08684 3/20 0.38
PIM1 P11309 2/20 0.38
PIM2 Q9P1W9 2/20 0.38
HTR6 P50406 1/20 0.38
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PIM3 Q86V86 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
AR P10275 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720702 0.84 PKN2 (0.43) CYP3A4CYP1A2CYP2C9CYP2C19
SCHEMBL4207683 0.76 CYP3A4 (0.48) HTR2CHTR2BCYP3A4PIM1PIM2
SCHEMBL6237278 0.75 RAB9A (0.52) MAOAMAOBCYP3A4RAB9AMEN1
SCHEMBL718663 0.73 CYP1A2 (0.46) HTR2CHTR2BDRD2CYP1A2KDM4E
SCHEMBL718662 0.73 HTR2C (0.47) HTR2CHTR2BDRD2CYP3A4HTR6
SCHEMBL13587710 0.72 RAB9A (0.50) MAOAMAOBCYP3A4RAB9AMEN1
SCHEMBL6307312 0.71 HTR2C (0.64) HTR2CHTR2BMAOBDRD2CYP3A4
SCHEMBL720033 0.71 NCF1 (0.42) HTR2CHTR2BDRD2MLNRHTR2A
SCHEMBL718762 0.70 NPC1 (0.44) HTR2CHTR2BDRD2CYP3A4HTR6
SCHEMBL10039876 0.70 RAB9A (0.55) CYP3A4RAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US claimed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO claimed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA2, CHRNA5, CHRNA10 HTR2C 253/4885HTR2B 268/4885MAOA 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.